EGF104900
Regimen
- Experimental
- Lapatinib 1000 mg PO daily + trastuzumab 2 mg/kg weekly.
- Control
- Lapatinib 1500 mg PO daily monotherapy.
Population
HER2-positive metastatic breast cancer with disease progression on prior trastuzumab-based regimens.
Key finding
EGF104900 was the first trial to prove dual HER2 blockade (lapatinib + trastuzumab) without chemotherapy improves OS in pretreated HER2+ MBC. Supported the mechanistic rationale that later drove CLEOPATRA and APHINITY.
Source: PMID 20124187
Timeline
- Publication: 2010 Mar 1
Guideline citations
- NCCN BREAST